Tavo Biotherapeutics
Founded 2024 · 14 employees on LinkedIn · 1 known investors
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.
Investors · 1
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $336K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $356.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $280K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Tavo Biotherapeutics do?
- Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.
- Who are Tavo Biotherapeutics's investors?
- Tavo Biotherapeutics's investors include Pureos Bioventures.